Source: Circulation. Unidade: FM
Subjects: DIRETRIZES PARA A PRÁTICA CLÍNICA, ISQUEMIA MIOCÁRDICA, DISLIPIDEMIAS, ENZIMAS PROTEOLÍTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROE, Matthew T et al. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, v. 140, n. 19, p. 1578-1589, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.042551. Acesso em: 16 out. 2024.APA
Roe, M. T., Li, Q. H., Bhatt, D. L., Bittner, V. A., Diaz, R., Goodman, S. G., et al. (2019). Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation, 140( 19), 1578-1589. doi:10.1161/CIRCULATIONAHA.119.042551NLM
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-jaramillo P, Nicolau JC. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes [Internet]. Circulation. 2019 ; 140( 19): 1578-1589.[citado 2024 out. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.042551Vancouver
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-jaramillo P, Nicolau JC. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes [Internet]. Circulation. 2019 ; 140( 19): 1578-1589.[citado 2024 out. 16 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.042551